Swedish Orphan Biovitrum ABSWOBY 67 EBITDA Margin % is 36.88% as of Mar. 2026, which is 2% above its 10-year median of 36.33. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 92.98% on this metric.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Swedish Orphan Biovitrum AB EBITDA Margin % Related Terms
Swedish Orphan Biovitrum AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a EBITDA Margin % of 36.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is near median its historical median of 36.33. Over the past decade, Swedish Orphan Biovitrum AB's EBITDA Margin % has ranged from 30.11 to 43.86. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #67 out of 955 companies in the Drug Manufacturers industry, placing it in the top 7%.
Is Swedish Orphan Biovitrum AB's EBITDA Margin % too high?
Swedish Orphan Biovitrum AB's current EBITDA Margin % of 36.88% is near median its 10-year median of 36.33. Over the past 10 years, this metric has ranged from a low of 30.11 to a high of 43.86. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Swedish Orphan Biovitrum AB's value of 36.88% is 197.7% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #67 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #67 out of 955 companies for EBITDA Margin %. This places Swedish Orphan Biovitrum AB in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Swedish Orphan Biovitrum AB's value of 36.88% is 197.7% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own EBITDA Margin % has ranged from 30.11 to 43.86 over the past decade. While the company's 10-year median is 36.33 vs. the industry median of 12.39, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current EBITDA Margin % of 36.88% is 197.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current EBITDA Margin % is 36.88%, which is near median its own 10-year median of 36.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current EBITDA Margin % is 36.88%, which is near median its 10-year median of 36.33 and 197.7% above the Drug Manufacturers industry median of 12.39. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current EBITDA Margin % is 36.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
EBITDA Margin %: 36.88% (near median its 10-year median of 36.33)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 197.7% above the Drug Manufacturers median (#67 of 955)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
